11 Most Undervalued US Stocks According to Analysts

Page 7 of 10

4. United Therapeutics Corporation (NASDAQ:UTHR)

Forward P/E Ratio as of June 25: 10.48

Number of Hedge Fund Holders: 43

Average Upside Potential as of June 25: 40.98%

United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts. On June 24, United Therapeutics Corporation and Intermountain Health announced a medical breakthrough: the world’s first patient treated in a clinical study with a bioengineered external liver assist product called miroliverELAP.

This historic procedure marked the first human clinical trial of a manufactured organ alternative and was performed at Intermountain Medical Center in Murray, Utah, by a team led by Christopher J. Danford, MD, who is a transplant hepatologist at Intermountain Health. The patient treated was experiencing liver failure and was not eligible for a liver transplant.

MiroliverELAP was developed by Miromatrix Medical Inc., which is a subsidiary of United Therapeutics and is an external liver assist combination product. It comprises a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit, designed to provide temporary liver support for patients with acute liver failure/ALF. ALF is a severe condition characterized by a rapid loss of liver function, often in individuals with no prior history of liver disease.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.

Page 7 of 10